Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99


Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer.

Qu Z, Fu J, Yan P, Hu J, Cheng SY, Xiao G.

J Biol Chem. 2010 Apr 16;285(16):11786-92. doi: 10.1074/jbc.M109.086561. Epub 2010 Feb 25.


DNA methylation-dependent repression of PDZ-LIM domain-containing protein 2 in colon cancer and its role as a potential therapeutic target.

Qu Z, Yan P, Fu J, Jiang J, Grusby MJ, Smithgall TE, Xiao G.

Cancer Res. 2010 Mar 1;70(5):1766-72. doi: 10.1158/0008-5472.CAN-09-3263. Epub 2010 Feb 9.


Epigenetic alteration of the NF-κB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer.

Yamamoto M, Ito T, Shimizu T, Ishida T, Semba K, Watanabe S, Yamaguchi N, Inoue J.

Cancer Sci. 2010 Nov;101(11):2391-7. doi: 10.1111/j.1349-7006.2010.01685.x. Epub 2010 Aug 24.


Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling.

Zhao L, Yu C, Zhou S, Lau WB, Lau B, Luo Z, Lin Q, Yang H, Xuan Y, Yi T, Zhao X, Wei Y.

Oncotarget. 2016 Jan 12;7(2):1408-20. doi: 10.18632/oncotarget.6368.


Global identification of genes regulated by estrogen signaling and demethylation in MCF-7 breast cancer cells.

Putnik M, Zhao C, Gustafsson JÅ, Dahlman-Wright K.

Biochem Biophys Res Commun. 2012 Sep 14;426(1):26-32. doi: 10.1016/j.bbrc.2012.08.007. Epub 2012 Aug 10.


[PDLIM2 and Its Role in Oncogenesis--Tumor Suppressor or Oncoprote?].

Maryáš J, Bouchal P.

Klin Onkol. 2015;28 Suppl 2:2S40-6. Review. Czech.


The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers.

Biswas DK, Dai SC, Cruz A, Weiser B, Graner E, Pardee AB.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10386-91. Epub 2001 Aug 21.


Sequestration of PDLIM2 in the cytoplasm of monocytic/macrophage cells is associated with adhesion and increased nuclear activity of NF-kappaB.

Healy NC, O'Connor R.

J Leukoc Biol. 2009 Mar;85(3):481-90. doi: 10.1189/jlb.0408238. Epub 2008 Dec 3.


Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.

Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr.

Mol Cell Biol. 1997 Jul;17(7):3629-39.


Essential function for PDLIM2 in cell polarization in three-dimensional cultures by feedback regulation of the β1-integrin-RhoA signaling axis.

Deevi RK, Cox OT, O'Connor R.

Neoplasia. 2014 May;16(5):422-31. doi: 10.1016/j.neo.2014.04.006. Epub 2014 May 23.


Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.

Borges S, Döppler H, Perez EA, Andorfer CA, Sun Z, Anastasiadis PZ, Thompson E, Geiger XJ, Storz P.

Breast Cancer Res. 2013 Aug 23;15(2):R66. doi: 10.1186/bcr3460.


A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFκB and STAT3 in colorectal cancer cells.

Liu S, Sun X, Wang M, Hou Y, Zhan Y, Jiang Y, Liu Z, Cao X, Chen P, Liu Z, Chen X, Tao Y, Xu C, Mao J, Cheng C, Li C, Hu Y, Wang L, Chin YE, Shi Y, Siebenlist U, Zhang X.

Gastroenterology. 2014 Oct;147(4):847-859.e11. doi: 10.1053/j.gastro.2014.06.006. Epub 2014 Jun 12.


Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer.

Fujikane T, Nishikawa N, Toyota M, Suzuki H, Nojima M, Maruyama R, Ashida M, Ohe-Toyota M, Kai M, Nishidate T, Sasaki Y, Ohmura T, Hirata K, Tokino T.

Breast Cancer Res Treat. 2010 Aug;122(3):699-710. doi: 10.1007/s10549-009-0600-1. Epub 2009 Oct 27.


NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells.

Gionet N, Jansson D, Mader S, Pratt MA.

J Cell Biochem. 2009 Jun 1;107(3):448-59. doi: 10.1002/jcb.22141.


Supplemental Content

Support Center